CLOSEOUT LETTER
Biotronik SE & Co. KG
- Recipient:
- Biotronik SE & Co. KG
United States
- Issuing Office:
United States
| |
10903 New Hampshire Avenue Silver Spring, MD 20993 |
VIA UNITED PARCEL SERVICE
NOV 06, 2017
Lothar Krings
Managing Director
Biotronik SE & Co. KG
Woermannkehre 1
12359 Berlin
Germany
Dear Dr. Krings:
The Food and Drug Administration has completed an evaluation of your firm's corrective actions in response to our Warning Letter (#500732 dated September 1, 2016). Based on our evaluation, it appears that you have addressed the violations contained in this Warning Letter. Future FDA inspections and regulatory activities will further assess the adequacy and sustainability of these corrections.
This letter does not relieve you or your firm from the responsibility of taking all necessary steps to assure sustained compliance with the Federal Food, Drug, and Cosmetic Act and its implementing regulations or with other relevant legal authority. The Agency expects you and your firm to maintain compliance and will continue to monitor your state of compliance. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means.
Sincerely yours,
/S/
Ronald Swann
Acting Director
Division of International Compliance Operations
Office of Compliance
Center for Devices and Radiological Health